The aim of the investigators study was to compare for the first time efficacy and safety of intravenously administered GLP-1 with an established intravenous insulin regimen in hyperglycaemic type 2 diabetic patients.
Intervention studies in patients with acute myocardial infraction or cardiac surgery, using intravenously administered human insulin, suggest that normalization of hyperglycemia can reduce morbidity as well as mortality in these patients. Insulin-based regimens require frequent blood glucose measurements and adjustments of infusion rate to achieve normoglycemia. In addition, hypoglycaemia is a frequent and important side effect. Glucagon-Like-Peptide 1 (GLP-1) is an insulinotropic, glucagonostatic gastrointestinal hormone that lowers glucose in a glycemia-dependent manner and therefore does not cause hypoglycemia. The aim of our study was to compare for the first time efficacy and safety of intravenously administered GLP-1 with an established intravenous insulin regimen in hyperglycaemic type 2 diabetic patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
8
Patients received GLP-1 intravenously at a dose of 1.2 pmol/kg/min for at maximum 8 hours.
Human regular insulin intravenously according to the Munich-registry.
Medical University of Graz, Department for Internal Medicine
Graz, Austria
time to reach a plasma glucose below 115 mg/dl
Time frame: 0,30,60,120,150,180,210,240,270,300,330,360,390,420,450,480,510 min
plasma glucose after 2 and 4 hours as well as maximum glycemia
Time frame: 0,30,60,120,150,180,210,240,270,300,330,360,390,420,450,480,510 min
number of hypoglycaemic episodes
Time frame: 0,30,60,120,150,180,210,240,270,300,330,360,390,420,450,480,510 min
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.